Literature DB >> 33948856

Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells.

Eda Acikgoz1, Gunel Mukhtarova2,3, Araz Alpay4, Cigir Biray Avci5, Bakiye Goker Bagca5, Gulperi Oktem6,7.   

Abstract

Cancer stem cells (CSCs) are a unique population that has been linked to drug resistance and metastasis and recurrence of prostate cancer. The sonic hedgehog (SHH) signal regulates stem cells in normal prostate epithelium by affecting cell behavior, survival, proliferation, and maintenance. Aberrant SHH pathway activation leads to an unsuitable expansion of stem cell lineages in the prostate epithelium and the transformation of prostate CSCs (PCSCs). Zoledronic acid (ZOL), one of the third-generation bisphosphonates, effectively prevented bone metastasis and treated advanced prostate cancer despite androgen deprivation therapy. Despite strong evidence for the involvement of the SHH in human PCSCs survival and drug resistance, the roles of SHH in the PCSCs-related resistance to ZOL remain to be fully elucidated. The present study aimed to investigate the role of the SHH pathway in ZOL resistance of PCSCs in 2D and three 3D cell culture conditions. For this purpose, we isolated CD133high/ CD44high PCSCs using a flow cytometer. Following ZOL treatment, mRNA and protein expressions of the components of the SHH signaling pathway in PCSCs and non-CSCs were analyzed using qRT-PCR and Immunofluorescence staining, respectively. Our finding suggested that SHH signaling may be activated by different mechanisms that lead to avoidance of the inhibition effect of ZOL. Thereby, SHH pathways may be associated with the resistance to ZOL developed by prostate CSCs. Inhibition of CSCs-related SHH signaling along with ZOL treatment should be considered to achieve improvement in survival or delayed treatment failure and prevention of the CSCs-related drug resistance.

Entities:  

Keywords:  Cancer stem cell; Drug resistance; Sonic hedgehog; Three-dimensional culture; Zoledronic acid

Year:  2021        PMID: 33948856     DOI: 10.1007/s11033-021-06387-w

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  43 in total

1.  Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis.

Authors:  H Rouhrazi; N Turgan; G Oktem
Journal:  Biotech Histochem       Date:  2018-01-04       Impact factor: 1.718

Review 2.  CD133 as a regulator of cancer metastasis through the cancer stem cells.

Authors:  Geou-Yarh Liou
Journal:  Int J Biochem Cell Biol       Date:  2018-11-03       Impact factor: 5.085

Review 3.  Targeting prostate cancer stem cells for cancer therapy.

Authors:  Guocan Wang; Zhiwei Wang; Fazlul H Sarkar; Wenyi Wei
Journal:  Discov Med       Date:  2012-02       Impact factor: 2.970

Review 4.  Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authors:  Axel S Merseburger; Joaquim Bellmunt; Cheryl Jenkins; Chris Parker; John M Fitzpatrick
Journal:  Oncologist       Date:  2013-05-13

5.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

6.  Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway.

Authors:  Suat Erdogan; Kader Turkekul; Ilker Dibirdik; Oguzhan Doganlar; Zeynep B Doganlar; Ayhan Bilir; Gulperi Oktem
Journal:  Biomed Pharmacother       Date:  2018-08-22       Impact factor: 6.529

Review 7.  Zoledronic acid: a review of its use in patients with advanced cancer.

Authors:  Caroline M Perry; David P Figgitt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.

Authors:  Caroline Wilson; Penelope Ottewell; Robert E Coleman; Ingunn Holen
Journal:  BMC Cancer       Date:  2015-02-14       Impact factor: 4.430

9.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

10.  FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis.

Authors:  Parthasarathy Seshacharyulu; Satyanarayana Rachagani; Sakthivel Muniyan; Jawed A Siddiqui; Eric Cruz; Sunandini Sharma; Ramakrishnan Krishnan; Brigham J Killips; Yuri Sheinin; Subodh M Lele; Lynette M Smith; Geoffrey A Talmon; Moorthy P Ponnusamy; Kaustubh Datta; Surinder K Batra
Journal:  Oncogene       Date:  2019-03-26       Impact factor: 9.867

View more
  2 in total

1.  Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients.

Authors:  Deyu Li; Na Li; Ying Ding
Journal:  Mol Clin Oncol       Date:  2022-08-01

Review 2.  Prostate Cancer Stem Cells: Clinical Aspects and Targeted Therapies.

Authors:  Isis Wolf; Christian Gratzke; Philipp Wolf
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.